Search Result

Pathways Recommended:	Anti-infection

Results for "

mouse infection model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (12) Bacterial (30) Beta-lactamase (1) Casein Kinase (1) Dengue Virus (2) Dihydrofolate reductase (DHFR) (2) DNA/RNA Synthesis (2) Endogenous Metabolite (2) FGFR (1) Flavivirus (1) Fungal (2) HBV (1) HIV (1) HSV (1) Influenza Virus (2) Liposome (1) Parasite (8) PD-1/PD-L1 (1) PI4K (1) Potassium Channel (1) Reactive Oxygen Species (ROS) (1) Reference Standards (4) RSV (2) SARS-CoV (3) VEGFR (1) Virus Protease (4) VSV (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Infection (51) Inflammation/Immunology (3) Metabolic Disease (3)

By Targets:

Antibiotic (12)

Bacterial (30)

Beta-lactamase (1)

Casein Kinase (1)

Dengue Virus (2)

Dihydrofolate reductase (DHFR) (2)

DNA/RNA Synthesis (2)

Endogenous Metabolite (2)

FGFR (1)

Flavivirus (1)

Fungal (2)

HBV (1)

HIV (1)

HSV (1)

Influenza Virus (2)

Liposome (1)

Parasite (8)

PD-1/PD-L1 (1)

PI4K (1)

Potassium Channel (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (4)

RSV (2)

SARS-CoV (3)

VEGFR (1)

Virus Protease (4)

VSV (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (1)

Infection (51)

Inflammation/Immunology (3)

Metabolic Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17035

Doramectin 5 Publications Verification	Parasite Antibiotic Bacterial	Infection
Doramectin is a derivative of Ivermectin (HY-15310). Doramectin is a potent antiparasitic antibiotic. Doramectin is an active compound against S.mansoni in an NMRI mouse infection model .

HY-156122

DHFR-IN-8	Dihydrofolate reductase (DHFR) Bacterial	Infection
DHFR-IN-8 (compound 6r) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-8 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC₅₀=15.6 ng/mL) in mouse models of systemic infection and thigh infection .

HY-156123

DHFR-IN-9	Dihydrofolate reductase (DHFR) Bacterial	Infection Cancer
DHFR-IN-9 (compound 8A) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-9 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC₅₀=0.25 μg/mL) and has anti-infective effects in mouse models of systemic infection and thigh infection caused by it (dose: 2.5 mg /kg, 5 mg/kg; ip). DHFR-IN-9 has stronger anticancer activity than paclitaxel (Y-B0015) in a mouse model of breast cancer (dose: 2.5 mg/kg; ip; once every 3 days) .

HY-P3350

LS-BF1	Bacterial	Infection
LS-BF1 is a stable and low toxic cationic antimicrobial peptide. LS-BF1 displays broad spectrum of antibacterial activity, including the challenging ESKAPE pathogens, by cell membrane disruptive mechanism. LS-BF1 shows good in vivo efficacy for elimination of bacteria in a mouse infection model[1].

HY-162818

Antibacterial agent 237	Bacterial Reactive Oxygen Species (ROS)	Infection
Antibacterial agent 237 (compound Ru-8) is a bacteriostatic agent for Staphylococcus aureus, with MIC of 0.78-1.56 μg/mL. Antibacterial agent 237 destroys bacterial cell membranes, changes their permeability, and induces bacteria to produce Reactive Oxygen Species, leading to bacterial death without causing drug resistance. Antibacterial agent 237 has low hemolytic toxicity to rabbit red blood cells and Raw 264.7 cells, and has significant antibacterial effects against Staphylococcus aureus in mouse skin wound infection models and Bacillus major larvae infection models .

HY-172349

JNJ-2901	Bacterial	Infection
JNJ-2901 is an inhibitor of M. tuberculosis cytochrome bc1:aa3. JNJ-2901 reduces bacterial load in the acute/chronic mouse infection models of M. tuberculosis H37Rv-ΔcydAB. JNJ-2901 can be used in tuberculosis (TB) research .

HY-173270

Antibacterial synergist 3	Bacterial	Infection
Antibacterial synergist 3 is a dual-acting inhibitor of biofilm (IC₅₀ of PAO1: 0.40 μM and IC₅₀ of PA14: 1.45 μM). Antibacterial synergist 3 reduces virulence production by inhibiting the quorum sensing (QS) system and induces iron deficiency in P. aeruginosa PAO1. Antibacterial synergist 3 enhances the efficacy of Tobramycin (HY-B0441) and Ciprofloxacin (HY-B0356) in a mouse wound infection model. Antibacterial synergist 3 can be used for the research of P. aeruginosa infections .

HY-163984

Antibacterial agent 240	Bacterial	Infection
Antibacterial agent 240 (compound 62-7c) is an antibacterial agent that can target multidrug-resistant (MDR) MRSA strains. Antibacterial agent 240 showed high biosafety and potent anti-infection activity in mouse pneumonia and mouse wound models of MRSA infection .

HY-117951

ANT431	Beta-lactamase	Infection
ANT431 is a metallo-β-lactamase inhibitor that also restores the effectiveness of Meropenem (HY-13678) in a mouse thigh Escherichia coli infection model .

HY-169102

CHIKV nsP2 protease-IN-1	Virus Protease	Infection
CHIKV nsP2 protease-IN-1(compound J13) is an oral active non-structural protein 2 protease inhibitor with the EC₅₀ of 0.39 μM aganist of CHIKV S27. CHIKV nsP2 protease-IN-1 can be used for study of Chikungunya virus .

HY-161065

HKI12134085	Bacterial	Infection
HKI12134085 (compound 3) is an orally available antibacterial nitrobenzothiazinone (BTZ) derivative with activity against Mycobacterium tuberculosis. HKI12134085 has in vivo inhibitory potency in a BALB/c mouse model of Mycobacterium tuberculosis infection .

HY-162144

BDM91288	Bacterial	Infection
BDM91288 is an orally active AcrB efflux pump inhibitor of pyridinium piperazine. BDM91288 can enhance the in vivo efficacy of levofloxacin (HY-B0330) in the treatment of Klebsiella pneumoniae pulmonary infection in mouse models .

HY-163069

Antitubercular agent-43	Bacterial	Infection
Antitubercular agent-43 (compound A11) is an orally active and potent antitubercular agent. Antitubercular agent-43 shows highly metabolic stability against human and mouse cytochrome P450 enzymes. Antitubercular agent-43 exhibits bactericidal efficacy in acute TB infection mouse model .

HY-17035R

Doramectin (Standard)	Reference Standards Parasite Antibiotic Bacterial	Infection
Doramectin (Standard) is the analytical standard of Doramectin. This product is intended for research and analytical applications. Doramectin is a derivative of Ivermectin (HY-15310). Doramectin is a potent antiparasitic antibiotic. Doramectin is an active compound against S.mansoni in an NMRI mouse infection model .

HY-169092

PF-07957472	SARS-CoV Virus Protease	Infection
PF-07957472 (Compound 4) is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor. PF-07957472 shows cytopathic effect in SARS-CoV-2 infected NHBE cells (EC₅₀ = 13.9 nM). PF-07957472 shows antiviral effect in a mouse-adapted model of COVID-19 infection model .

HY-118338

WRR-483	Parasite	Infection
WRR-483 is an analog of K11777, an inhibitor of cruzain, used to inhibit the proliferation of Trypanosoma cruzi in cell culture. WRR-483 can eradicate parasitic infection in an acute Chagas disease mouse model. WRR-483 is an irreversible cysteine protease inhibitor that shows pH-dependent high affinity and potent trypanocidal activity against cruzain and T. cruzi infection, and is expected to inhibit Chagas disease.

HY-168045

HBV-IN-48	HBV DNA/RNA Synthesis	Infection
HBV-IN-48 is an HBV inhibitor. HBV-IN-48 has antiviral activity against HBV in HepDE19 cells, with an EC₅₀ value of 0.005 μM. HBV-IN-48 can reduce serum HBV DNA levels in mouse models of HBV infection .

HY-120777

GSK729	Bacterial	Others
GSK729 is a THPP inhibitor with the activity of inhibiting EchA6 and inhibiting Mycobacterium tuberculosis. GSK729 can selectively pull down EchA6 in a stereospecific manner, inhibit its activity, inhibit fatty acid synthesis of Mycobacterium tuberculosis, and has a bactericidal effect in a mouse chronic tuberculosis infection model.

HY-139602

(+)-JNJ-A07 2 Publications Verification	Flavivirus Dengue Virus Virus Protease	Infection
(+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+)-JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+)-JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models .

HY-148178

MMV688533	Parasite	Infection
MMV688533 is an antimalarial agent with rapid anti-plasmodial activity and effective single-dose activity against Plasmodium falciparum infection in humanized mouse models. MMV688533 can inhibit the activity of asexual blood stage parasites with an IC₅₀ value of 1.3 nM. MMV688533 exhibits excellent pharmacokinetic properties and safety .

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .

HY-173312

Antimalarial agent 49	Parasite	Infection
Antimalarial agent 49 is an orally active antimalarial compound. Antimalarial agent 49 inhibits growth of Pf3D7 and PfK1 strains (IC₅₀: 0.84 μM and 0.4 μM respectively). Antimalarial agent 49 has antimalarial activity and inhibits the development of P. berghei liver stages. Antimalarial agent 49 can be used in the study of Plasmodium infection .

HY-B1864C

Kasugamycin sulfate Ksg sulfate	Antibiotic Bacterial	Infection
Kasugamycin (Ksg) hydrochloride hydrate is an antibiotic that binds to 30s and 70s ribosomes but not to the 50s subunit, and has anti-infective activity. Kasugamycin hydrochloride hydrate mimics mRNA nucleotides, disrupts tRNA binding and inhibits canonical translation initiation. Kasugamycin hydrochloride hydrate increases the sensitivity of mycobacteria to Rifampicin (HY-B0272) in vitro and in mouse infection models .

HY-B1864B

Kasugamycin hydrochloride hydrate 1 Publications Verification Ksg hydrochloride hydrate	Antibiotic Bacterial	Infection
Kasugamycin (Ksg) hydrochloride hydrate is an antibiotic that binds to 30s and 70s ribosomes but not to the 50s subunit, and has anti-infective activity. Kasugamycin hydrochloride hydrate mimics mRNA nucleotides, disrupts tRNA binding and inhibits canonical translation initiation. Kasugamycin hydrochloride hydrate increases the sensitivity of mycobacteria to Rifampicin (HY-B0272) in vitro and in mouse infection models .

HY-B1864A

Kasugamycin hydrochloride 1 Publications Verification Ksg hydrochloride	Antibiotic Bacterial	Infection
Kasugamycin (Ksg) hydrochloride hydrate is an antibiotic that binds to 30s and 70s ribosomes but not to the 50s subunit, and has anti-infective activity. Kasugamycin hydrochloride hydrate mimics mRNA nucleotides, disrupts tRNA binding and inhibits canonical translation initiation. Kasugamycin hydrochloride hydrate increases the sensitivity of mycobacteria to Rifampicin (HY-B0272) in vitro and in mouse infection models .

HY-172953

Insecticidal agent 24	Parasite	Infection
Insecticidal agent 24 is an orally active pyridylspiroindoline frontrunner. Insecticidal agent 24 has antiplasmodial activity (Pf NF54 IC₅₀: 0.08 μM). Insecticidal agent 24 inhibits hERG activity (IC₅₀: 6.5 μM). Insecticidal agent 24 reduces parasitemia in a humanized immunodeficient NSG mouse Plasmodium falciparum infection model .

HY-142221

ARB-272572	PD-1/PD-L1	Cancer
ARB-272572 is an oral effective small molecule PD-L1 inhibitor, with an IC₅₀ value of 400 pM. ARB-272572 has research significance in tumors and chronic viral infections .

HY-167935

LCC-12 formic	Bacterial	Metabolic Disease Inflammation/Immunology
LCC-12 formic is a dimer of metformin that targets mitochondrial copper(II), leading to a decrease in the NAD(H) pool and modulation of inflammatory responses. LCC-12 formic reduces inflammation in mouse models of bacterial and viral infections. LCC-12 formic also serves as a tool for investigating metabolic diseases through its effects on cell plasticity and epigenetic programming.

HY-19925

AIC-292	HIV	Infection
AIC-292 is a potent and selective inhibitor of HIV-1 nonnucleoside reverse transcriptase. AIC-292 inhibits wild-type HIV-1 laboratory strains at low nanomolar concentrations. AIC-292 displays potent antiviral in vivo efficacy in a mouse xenograft model. AIC-292 has the potential for the research of HIV-1 infection .

HY-172264

XT17	Antibiotic Bacterial DNA/RNA Synthesis	Infection
XT17 is an anthrone compound with broad-spectrum antibacterial activity. It exerts its antibacterial effect by disrupting the cell wall and inhibiting DNA synthesis. XT17 exhibits weak hemolytic activity, low cytotoxicity against mammalian cell lines, and a low frequency of drug resistance. Meanwhile, XT17 shows in vivo efficacy in a mouse corneal infection model induced by Staphylococcus aureus or Pseudomonas aeruginosa. Further docking studies have confirmed that XT17 can form a stable complex with bacterial gyrase. XT17 can be used in the research of the anti - infection field .

HY-168998

Yck2-IN-1	Fungal Casein Kinase	Infection
Yck2-IN-1 (Compound 2a) is an inhibitor of the fungal Candida albicans Yck2 kinase. It exhibits an IC₅₀ of approximately 80 nM against Yck2 and a MIC₈₀ of 12.5 µM against C. albicans, with good metabolic stability (66% remaining in mouse liver microsomes). In a mouse model of drug-resistant candidiasis, Yck2-IN-1 significantly reduced fungal burden in the kidneys. Yck2-IN-1 holds promise for research in the field of antifungal infection .

HY-147429

Zosurabalpin Abx MCP; RG6006	Bacterial Antibiotic	Infection
Zosurabalpin is a polypeptide antibiotic targeting LPS transporter (LptB₂FGC complex), which can block the transport of LPS and lead to endotoxin accumulation in cells, and has shown excellent antibacterial activity against Carbapenem-resistant Acinetobacter baumanni (CRAB) .

HY-113365

Cholestenone 4-Cholesten-3-one	Endogenous Metabolite	Infection Metabolic Disease
Cholestenone (4-cholesten-3-one) is an orally available antimicrobial agent that is metabolized primarily in the liver as an intermediate oxidation product of cholesterol. Cholestenone inhibits human dermal fibroblast migration and fights Helicobacter pylori infection in vitro and in mouse models by inhibiting cholesterol-α-D-glucopyranoside (CGL). Cholestenone also alleviates metabolic disorders caused by obesity in db/db mice .

HY-121365

Forphenicinol	Bacterial	Infection
Forphenicinol is an immunomodulator and a derivative of the bacterial metabolite forphenicine. It increases the phagocytosis of yeast by peritoneal macrophages isolated from thioglycolate-stimulated mice. Forphenicinol (100 μg/animal) prevents cyclophosphamide-induced suppression of delayed-type hypersensitivity (DTH), as well as enhances DTH in response to the hapten oxazolone or sheep red blood cells in mice. It enhances the bactericidal activity of macrophages against P. aeruginosa in mice when administered at a dose of 0.5 mg/kg.2 Forphenicinol (15.6-1,000 μg/animal) increases survival in a mouse model of P. aeruginosa infection. It also inhibits tumor growth in S180 sarcoma and IMC carcinoma mouse xenograft models when administered at doses ranging from 0.05 to 5 mg/kg per day.

HY-165603

Si5-N14	Liposome VEGFR FGFR	Cardiovascular Disease Inflammation/Immunology Cancer
Si5-N14 is a key component of siloxane-incorporated lipid nanoparticles (SiLNP), possessing pro-vascular repair and anti-tumor activities. In the transgenic GFP mouse model, Si5-N14 can mediate CRISPR-Cas9 editing. In the Lewis lung carcinoma (LLC) tumor-bearing mouse model, Si5-N14 can knock out the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) to exert an anti-tumor effect. In a mouse model of lung injury induced by viral infection, the delivery of Fibroblast Growth Factor-2 (FGF-2) mRNA via Si5-N14 can promote vascular repair, increase blood oxygen levels, and improve lung function. Si5-N14 shows promise for research in the fields of oncology, pneumonia, and cardiovascular diseases .

HY-134090

9-Methylstreptimidone Antibiotic TS 885; NSC 248958	Bacterial VSV	Infection
9-Methylstreptimidone is a microbial metabolite originally isolated from Streptomyces sp. S-885 that has antifungal and antiviral activities. It is active against several fungi, including S. sake, S. fragilis, R. rubra, T. rubra, and C. albidus (MICs=4-20 μg/mL) and has antiviral activity against poliovirus, vesicular stomatitis virus (VSV), and Newcastle disease virus (NDV) in vitro (MIC=0.02 μg/mL for all). 9-Methylstreptimidone increases survival in mouse models of infection with influenza A2 (H2N2) or C. albicans when administered prior to infection.

HY-162680

OSC-GCDI(P)	Influenza Virus	Infection
OSC-GCDI(P) is a broad-spectrum orally active anti-influenza virus agent that exhibits significant inhibitory effects against both wild-type and Oseltamivir (HY-13317) resistant (H275Y) influenza virus strains in mouse infection models. OSC-GCDI(P) is capable of preventing not only wild-type influenza viruses but also OS-resistant variants with NA(H275Y) .

HY-P10913

HYNIC-UBI29-41	Bacterial	Infection
HYNIC-UBI29-41 is composed of a bifunctional chelator HYNIC and an antimicrobial peptide UBI 29-41. HYNIC-UBI29-41 retains the antibacterial properties of UBI 29-41, and exhibits good affinity to Gram-positive and Gram-negative bacteria. HYNIC-UBI29-41 can be used as an imaging agent for bacterial infection detection in mouse models, when labeled with the radioactive element technetium (99mTc) .

HY-N14354

Ferrocin B	Antibiotic Bacterial	Infection
Ferrocin B is an iron-containing cyclic decapeptide antibiotic found in the bacterium Pseudomonas fluorescens YK-310, exhibiting strong antibacterial activity primarily against Gram-negative bacteria, with particularly potent inhibitory effects on Pseudomonas aeruginosa. In a mouse infection model, Ferrocin B shows a half effective dose (ED₅₀) of 0.593 mg/kg against P. aeruginosa. Ferrocin B holds potential for research in the field of anti-infective therapies .

HY-B1864AR

Kasugamycin hydrochloride (Standard) Ksg hydrochloride (Standard)	Reference Standards Antibiotic Bacterial	Infection
Kasugamycin (Ksg) hydrochloride (Standard) is the analytical standard of Kasugamycin hydrochloride (HY-B1864A). This product is intended for research and analytical applications. Kasugamycin (Ksg) hydrochloride hydrate is an antibiotic that binds to 30s and 70s ribosomes but not to the 50s subunit, and has anti-infective activity. Kasugamycin hydrochloride hydrate mimics mRNA nucleotides, disrupts tRNA binding and inhibits canonical translation initiation. Kasugamycin hydrochloride hydrate increases the sensitivity of mycobacteria to Rifampicin (HY-B0272) in vitro and in mouse infection models .

HY-16911

AFN-1252 Maximum Cited Publications 10 Publications Verification API-1252; Debio 1452	Bacterial Antibiotic	Infection
AFN-1252 is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 exhibits typical MIC₉₀ values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith .

HY-124623

DNDI-8219	Parasite	Infection
DNDI-8219 (compound 58) is a potent selective and orally active trypanocidal agent, possessing inhibitory activity against Trypanosoma cruzi (T. cruzi) with an IC50 of 0.4 μM. DNDI-8219 has low cytotoxicity (L6 cells IC50 > 100 μM). DNDI-8219 can effectively cure chronic T. cruzi infection and markedly reduce parasite burdens in mouse model. DNDI-8219 has good solubility, metabolic stability and safety.

HY-B1864BR

Kasugamycin hydrochloride hydrate (Standard) Ksg hydrochloride hydrate (Standard)	Reference Standards Antibiotic Bacterial	Infection
Kasugamycin (Ksg) hydrochloride hydrate (Standard) is the analytical standard of Kasugamycin hydrochloride hydrate (HY-B1864B). This product is intended for research and analytical applications. Kasugamycin (Ksg) hydrochloride hydrate is an antibiotic that binds to 30s and 70s ribosomes but not to the 50s subunit, and has anti-infective activity. Kasugamycin hydrochloride hydrate mimics mRNA nucleotides, disrupts tRNA binding and inhibits canonical translation initiation. Kasugamycin hydrochloride hydrate increases the sensitivity of mycobacteria to Rifampicin (HY-B0272) in vitro and in mouse infection models .

HY-114622

AFN-1252 tosylate API-1252 tosylate; Debio 1452 tosylate	Bacterial Antibiotic	Infection
AFN-1252 (API-1252) tosylate is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 tosylate exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 tosylate exhibits typical MIC₉₀ values of 0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 tosylate is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith .

HY-163765

Antimalarial agent 41	PI4K Potassium Channel	Infection
Antimalarial agent 41 (Compound 17) exhibits antimalarial activity, which inhibits Plasmodium falciparum with an IC₅₀ of 40 nM (NF54 strain) and 76 nM (K1 strain). Antimalarial agent 41 is an inhibitor for P. falciparum phosphatidylinositol-4-kinase β (Pf PI4K) and hERG channel, with an IC₅₀ of 53 nM and 3 μM. Antimalarial agent 41 exhibits cytotoxicity to CHO cells with an IC₅₀ of 34 μM. Antimalarial agent 41 ameliorates the malaria infection and exhibits good pharmacokinetic characters in mouse models .

HY-19487

Ribocil	Bacterial	Infection
Ribocil is a selective inhibitor targeting the bacterial FMN riboswitch, regulating the bacterial riboflavin riboswitch. Ribocil competitively binds to the FMN binding site, mimicking the natural ligand FMN to induce conformational changes in the riboswitch, inhibiting ribB gene expression, reducing riboflavin synthesis, and thus inhibiting bacterial growth. Ribocil strongly inhibits GFP expression (EC₅₀=0.3 μM). Ribocil exhibits in vivo antibacterial activity in a mouse model and can be used to study antibacterial drugs related to drug-resistant bacterial infections and bacterial riboflavin metabolic pathways[1][2].

HY-154968

RSV L-protein-IN-5	RSV	Infection
RSV L-protein-IN-5 (compound E) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC₅₀=0.1 μM). RSV L-protein-IN-5 inhibits Polymerase (IC₅₀=0.66 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-5 shows moderate cytotoxicity (CC50=10.7 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .

HY-115574

RSV L-protein-IN-1	RSV	Infection
RSV L-protein-IN-1 (compound D) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC₅₀=0.021 μM). RSV L-protein-IN-1 inhibits Polymerase (IC₅₀=0.089 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .

HY-168729

Antibacterial agent 256	Bacterial	Infection
Antibacterial agent 256 (Compound C09) is an inhibitor for type I signal peptidase (SPase I). Antibacterial agent 256 inhibits gram-positive bacteria, that inhibits S. aureus ATCC 29213, E. faecium QF31, E. faecalis SF23-1 and S. suis P1/7, with MIC of 1-16 μg/mL. Antibacterial agent 256 exhibits cytotoxicity in cancer cell HEp-2 and Caco-2 with CC₅₀ of 14.65 μg/mL and 21.93 μg/mL. Antibacterial agent 256 exhibits a hemolytic activity on mouse RBCs, with an HC₅₀ of 13.29 μg/mL. Antibacterial agent 256 ameliorates the MRSA skin infection in mouse model .

HY-155731

Antiviral agent 35	Influenza Virus	Infection
Antiviral agent 35 (compound 4d) is an orally active and potent influenza virus inhibitor, acting function in the early stage of virus replication. Antiviral agent 35 inhibits ROS accumulation, autophagy and apoptosis induced by influenza virus, and also inhibits inflammatory response mediated by RIG-1 pathway in mouse model with pulmonary infection. Antiviral agent 35 shows little cytotoxicity with CC₅₀ >800 μM in MDCK cells, and anti-H1N1 (A/Weiss/43) activity with EC₅₀ of 2.28 μM .

Cat. No.	Product Name	Target	Research Area